LTPA2017017I1 - Tetraciklinis junginys - Google Patents

Tetraciklinis junginys

Info

Publication number
LTPA2017017I1
LTPA2017017I1 LTPA2017017C LTPA2017017C LTPA2017017I1 LT PA2017017 I1 LTPA2017017 I1 LT PA2017017I1 LT PA2017017 C LTPA2017017 C LT PA2017017C LT PA2017017 C LTPA2017017 C LT PA2017017C LT PA2017017 I1 LTPA2017017 I1 LT PA2017017I1
Authority
LT
Lithuania
Prior art keywords
tetracyclic compound
tetracyclic
compound
Prior art date
Application number
LTPA2017017C
Other languages
English (en)
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43308919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2017017(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of LTPA2017017I1 publication Critical patent/LTPA2017017I1/lt
Publication of LTC2441753I2 publication Critical patent/LTC2441753I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
LTPA2017017C 2009-06-10 2017-06-02 Tetraciklinis junginys LTC2441753I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009139691 2009-06-10
PCT/JP2010/059785 WO2010143664A1 (ja) 2009-06-10 2010-06-09 ４環性化合物

Publications (2)

Publication Number Publication Date
LTPA2017017I1 true LTPA2017017I1 (lt) 2017-06-26
LTC2441753I2 LTC2441753I2 (lt) 2019-02-25

Family

ID=43308919

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP15180863.1T LT2975024T (lt) 2009-06-10 2010-06-09 Tetraciklininiai junginiai
LT18158255T LT3345903T (lt) 2009-06-10 2010-06-09 Tetracikliniai junginiai
LTPA2017017C LTC2441753I2 (lt) 2009-06-10 2017-06-02 Tetraciklinis junginys

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP15180863.1T LT2975024T (lt) 2009-06-10 2010-06-09 Tetraciklininiai junginiai
LT18158255T LT3345903T (lt) 2009-06-10 2010-06-09 Tetracikliniai junginiai

Country Status (39)

Country Link
US (6) US9126931B2 (lt)
EP (4) EP3613729A1 (lt)
JP (2) JP4588121B1 (lt)
KR (1) KR101351120B1 (lt)
CN (1) CN102459172B (lt)
AR (1) AR077025A1 (lt)
AU (1) AU2010259588B2 (lt)
CA (1) CA2764653C (lt)
CL (1) CL2011002433A1 (lt)
CO (1) CO6430460A2 (lt)
CR (1) CR20110492A (lt)
CY (2) CY1117752T1 (lt)
DK (3) DK3345903T3 (lt)
EC (1) ECSP12011573A (lt)
ES (3) ES2759510T3 (lt)
FR (1) FR17C1019I2 (lt)
HK (1) HK1165794A1 (lt)
HR (3) HRP20160605T1 (lt)
HU (4) HUE039167T2 (lt)
IL (1) IL216817A (lt)
LT (3) LT2975024T (lt)
LU (1) LUC00022I2 (lt)
MA (1) MA33418B1 (lt)
MX (1) MX2011013306A (lt)
MY (1) MY159850A (lt)
NL (1) NL300876I2 (lt)
NO (2) NO2975024T3 (lt)
NZ (1) NZ597477A (lt)
PE (1) PE20121065A1 (lt)
PL (3) PL2441753T3 (lt)
PT (3) PT2441753E (lt)
RS (1) RS58855B1 (lt)
RU (2) RU2585622C3 (lt)
SG (1) SG175707A1 (lt)
SI (3) SI2975024T1 (lt)
TW (2) TWI531367B (lt)
UA (1) UA107796C2 (lt)
WO (1) WO2010143664A1 (lt)
ZA (1) ZA201106938B (lt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143664A1 (ja) * 2009-06-10 2010-12-16 中外製薬株式会社 ４環性化合物
WO2012023597A1 (ja) 2010-08-20 2012-02-23 中外製薬株式会社 ４環性化合物を含む組成物
JP5006987B2 (ja) * 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
EP3815685A3 (en) * 2011-10-31 2021-10-13 The Methodist Hospital Research Institute Compound comprising a mao targeting/seeker moiety for treating human gliomas
WO2013134353A1 (en) 2012-03-06 2013-09-12 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
AU2013321235B2 (en) 2012-09-25 2017-07-20 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
JP2016503798A (ja) 2012-12-20 2016-02-08 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化ａｌｋ阻害剤
CN104968667B (zh) * 2013-02-05 2017-06-20 山东轩竹医药科技有限公司 四并环激酶抑制剂
CA2907663A1 (en) 2013-04-02 2014-10-09 Respivert Limited Urea derivatives useful as kinase inhibitors
CN104109168B (zh) * 2013-04-20 2017-02-15 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104130241A (zh) * 2013-05-05 2014-11-05 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104177332A (zh) * 2013-05-20 2014-12-03 中国科学院上海药物研究所 酰胺基取代的吲哚并萘酮衍生物及其医药用途
CN104177342B (zh) * 2013-05-21 2018-01-05 中国科学院上海药物研究所 杂环基取代的吲哚并萘酮衍生物及其医药用途
WO2014190949A1 (zh) * 2013-06-01 2014-12-04 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
KR20160020502A (ko) 2013-06-18 2016-02-23 노파르티스 아게 제약 조합물
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
CA2946268A1 (en) 2014-04-25 2015-10-29 Chugai Seiyaku Kabushiki Kaisha Crystal of tetracyclic compound
EP3135287A4 (en) 2014-04-25 2018-01-03 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
CA2942186C (en) * 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
TWI803187B (zh) * 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
KR101909404B1 (ko) 2014-09-29 2018-10-17 수안주 파마 코포레이션 리미티드 역형성 림프종 키나제의 폴리사이클릭 저해제
CN105566307B (zh) * 2014-10-11 2019-04-23 中国科学院上海药物研究所 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
KR102584344B1 (ko) 2015-01-16 2023-09-27 추가이 세이야쿠 가부시키가이샤 병용 의약
US9573932B2 (en) * 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2016145288A1 (en) * 2015-03-11 2016-09-15 International Flavors & Fragrances Inc. Processes for the preparation of unsaturated malonates
AU2016251253B2 (en) 2015-04-24 2020-07-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
US10508082B2 (en) 2015-09-23 2019-12-17 Dana-Farber Cancer Institute, Inc. Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK
CN105777710B (zh) * 2016-04-05 2018-09-04 湖南欧亚药业有限公司 一种艾乐替尼的合成方法
CN106946650B (zh) * 2017-03-01 2021-06-08 南京远淑医药科技有限公司 一种盐酸阿雷替尼中间体的合成方法
CN106928185B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107129488A (zh) * 2017-04-21 2017-09-05 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
CN106995433A (zh) * 2017-04-21 2017-08-01 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
CN106928184B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106892860B (zh) * 2017-04-21 2019-08-02 湖南博奥德药业有限公司 一种艾乐替尼中间体的制备方法
CN106928125A (zh) * 2017-04-21 2017-07-07 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼中间体的制备方法
CN107033125B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
BR112019022137A2 (pt) 2017-05-04 2020-05-12 Basf Se Usos de compostos, compostos da fórmula i, composição agroquímica e método para combater fungos nocivos fitopatogênicos
EP3649116A1 (en) * 2017-07-05 2020-05-13 Fresenius Kabi Oncology Limited A process for preparing alectinib or a pharmaceutically acceptable salt thereof
JP7054134B2 (ja) * 2017-12-07 2022-04-13 国立大学法人京都大学 ベンゾ［ｂ］カルバゾール化合物及びそれを用いたイメージング
AU2018382122B2 (en) * 2017-12-13 2021-11-18 Shanghaitech University ALK protein degradation agent and anti-tumor application thereof
CN108178743A (zh) * 2018-02-08 2018-06-19 安庆奇创药业有限公司 一种艾乐替尼关键中间体的制备方法
US20220117982A1 (en) * 2018-04-09 2022-04-21 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
WO2019211868A1 (en) * 2018-04-30 2019-11-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile hydrochloride
CN112384223A (zh) 2018-06-29 2021-02-19 中外制药株式会社 含有难溶性碱性药剂的药物组合物
CA3107270A1 (en) * 2018-09-04 2020-03-12 Chugai Seiyaku Kabushiki Kaisha Method for producing tetracyclic compound
EP3856192A4 (en) * 2018-09-27 2023-01-04 Dana Farber Cancer Institute, Inc. ALK-TARGETING DEGRADING AGENTS AND THEIR THERAPEUTIC USES
CN109438218B (zh) * 2018-10-23 2021-04-09 成都艾必克医药科技有限公司 一种盐酸艾乐替尼中间体2-(4-乙基-3-碘苯基)-2-甲基丙酸的合成方法
CN109384664B (zh) * 2018-11-20 2021-04-13 成都正善达生物医药科技有限公司 一种艾乐替尼中间体的制备方法
EP3556754A1 (en) 2018-12-07 2019-10-23 Fresenius Kabi iPSUM S.r.l. Process for the preparation of alectinib
CN111349012B (zh) * 2018-12-21 2023-01-10 上海复星星泰医药科技有限公司 一种卤代芳烃类化合物的制备方法及其中间体
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN110590739A (zh) * 2019-09-20 2019-12-20 中国药科大学 一种艾乐替尼的制备方法
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116806152A (zh) 2021-01-29 2023-09-26 中外制药株式会社 儿童癌症治疗用药物组合物
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115340523B (zh) * 2021-05-12 2023-12-15 盛世泰科生物医药技术(苏州)股份有限公司 一种具有alk抑制活性的化合物及其制备方法和用途
WO2023161233A1 (en) * 2022-02-22 2023-08-31 Synthon B.V. Solid forms of alectinib and alectinib salts
CN115677659B (zh) * 2022-10-11 2024-03-22 枣庄市润安制药新材料有限公司 一种阿雷替尼的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892090A (ja) * 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
DE69505470T2 (de) 1994-08-04 1999-05-12 Hoffmann La Roche Pyrrolocarbazol
JPH08291285A (ja) * 1995-04-21 1996-11-05 Fuji Photo Film Co Ltd 感光性組成物及びそれを用いた要素
PL329681A1 (en) * 1996-05-01 1999-04-12 Lilly Co Eli Halogen-substituted inhibitor of proteinous kinase c
EP1178988B1 (en) * 1999-05-14 2007-02-28 The Australian National University Compounds and therapeutic methods
US7217709B2 (en) * 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
ES2263862T3 (es) * 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
WO2005054237A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
CA2548600A1 (en) 2003-12-12 2005-06-23 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
CN1934082A (zh) 2004-03-19 2007-03-21 斯皮德尔实验股份公司 有机化合物
EP1730128A1 (en) 2004-03-31 2006-12-13 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
EA013678B1 (ru) * 2004-08-26 2010-06-30 Пфайзер Инк. Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
KR20080056288A (ko) * 2005-11-07 2008-06-20 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) * 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CL2007003049A1 (es) * 2006-10-23 2008-05-16 Cephalon Inc Pharmacopeia Drug Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
CN101754956B (zh) 2007-07-20 2014-04-23 内尔维阿诺医学科学有限公司 作为具有激酶抑制剂活性的取代的吲唑衍生物
CA2707308C (en) 2007-11-30 2016-08-02 Newlink Genetics Corporation Ido inhibitors
EA201190235A1 (ru) 2009-05-07 2012-05-30 Астразенека Аб Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2010143664A1 (ja) * 2009-06-10 2010-12-16 中外製薬株式会社 ４環性化合物
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
WO2012023597A1 (ja) * 2010-08-20 2012-02-23 中外製薬株式会社 ４環性化合物を含む組成物
AU2013321235B2 (en) * 2012-09-25 2017-07-20 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
EP3135287A4 (en) * 2014-04-25 2018-01-03 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
CA2946268A1 (en) * 2014-04-25 2015-10-29 Chugai Seiyaku Kabushiki Kaisha Crystal of tetracyclic compound
CA2942186C (en) * 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
TWI803187B (zh) * 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑

Also Published As

Publication number Publication date
CY1117752T1 (el) 2017-05-17
LT3345903T (lt) 2019-12-10
UA107796C2 (en) 2015-02-25
ZA201106938B (en) 2012-12-27
EP2975024A1 (en) 2016-01-20
EP2441753A1 (en) 2012-04-18
EP2975024B1 (en) 2018-03-28
RS20110548A1 (en) 2012-08-31
HUE039167T2 (hu) 2018-12-28
FR17C1019I1 (lt) 2017-07-21
US20160340308A1 (en) 2016-11-24
MA33418B1 (fr) 2012-07-03
EP3345903B1 (en) 2019-10-09
ES2668775T3 (es) 2018-05-22
TWI531367B (zh) 2016-05-01
EP2441753A4 (en) 2014-08-27
US20220306578A1 (en) 2022-09-29
CY2017026I1 (el) 2017-11-14
RU2015156881A3 (lt) 2019-08-08
LT2975024T (lt) 2018-06-11
CL2011002433A1 (es) 2012-02-17
SG175707A1 (en) 2011-12-29
PT2975024T (pt) 2018-05-14
CO6430460A2 (es) 2012-04-30
EP3613729A1 (en) 2020-02-26
CA2764653C (en) 2018-01-02
KR101351120B1 (ko) 2014-01-15
TW201613858A (en) 2016-04-16
AR077025A1 (es) 2011-07-27
NL300876I2 (nl) 2017-07-11
PL2975024T3 (pl) 2018-09-28
PT2441753E (pt) 2016-06-16
NO2017026I1 (no) 2017-06-12
PL2441753T3 (pl) 2016-09-30
RU2585622C2 (ru) 2016-05-27
TW201103537A (en) 2011-02-01
IL216817A0 (en) 2012-02-29
ES2575084T3 (es) 2016-06-24
US9440922B2 (en) 2016-09-13
HUE028278T2 (en) 2016-12-28
JP5628603B2 (ja) 2014-11-19
RU2725140C2 (ru) 2020-06-30
IL216817A (en) 2016-05-31
TWI624457B (zh) 2018-05-21
FR17C1019I2 (fr) 2018-04-27
DK2441753T3 (en) 2016-05-30
MY159850A (en) 2017-02-15
PE20121065A1 (es) 2012-08-28
HK1165794A1 (en) 2012-10-12
US20200017442A1 (en) 2020-01-16
LTC2441753I2 (lt) 2019-02-25
CA2764653A1 (en) 2010-12-16
RU2585622C3 (ru) 2021-08-02
AU2010259588A1 (en) 2011-10-06
US20120083488A1 (en) 2012-04-05
SI2441753T1 (sl) 2016-07-29
NL300876I1 (nl) 2017-06-14
HRP20192022T1 (hr) 2020-02-07
JPWO2010143664A1 (ja) 2012-11-29
DK3345903T3 (da) 2019-11-11
LUC00022I1 (lt) 2017-06-15
ES2759510T3 (es) 2020-05-11
NO2975024T3 (lt) 2018-08-25
HUS1700026I1 (hu) 2017-07-28
LUC00022I2 (lt) 2017-09-08
HRP20180615T1 (hr) 2018-06-01
NZ597477A (en) 2014-03-28
US20230142119A1 (en) 2023-05-11
RU2015156881A (ru) 2019-01-18
CN102459172B (zh) 2015-06-24
WO2010143664A1 (ja) 2010-12-16
EP2441753B1 (en) 2016-03-30
BRPI1011649A2 (pt) 2021-04-20
SI3345903T1 (sl) 2020-02-28
US20150150845A1 (en) 2015-06-04
US9126931B2 (en) 2015-09-08
DK2975024T3 (en) 2018-04-23
EP3345903A1 (en) 2018-07-11
JP4588121B1 (ja) 2010-11-24
HRP20160605T1 (hr) 2016-07-01
HUE046402T2 (hu) 2020-03-30
JP2011016830A (ja) 2011-01-27
SI2975024T1 (en) 2018-05-31
MX2011013306A (es) 2012-01-12
PL3345903T3 (pl) 2020-02-28
PT3345903T (pt) 2019-12-09
RU2011154150A (ru) 2013-07-20
RS58855B1 (sr) 2019-07-31
ECSP12011573A (es) 2012-02-29
CN102459172A (zh) 2012-05-16
CR20110492A (es) 2012-03-08
KR20120034677A (ko) 2012-04-12
AU2010259588B2 (en) 2015-05-28
CY2017026I2 (el) 2017-11-14
NO2017026I2 (no) 2017-06-12

Similar Documents

Publication Publication Date Title
LTPA2017017I1 (lt) Tetraciklinis junginys
LTPA2020505I1 (lt) Nauji tricikliniai junginiai
BR112012006859A2 (pt) compostos
DK2427449T3 (da) Vinylindazolylforbindelser
BRPI1013868A2 (pt) composto diaciletilenodiamina
BRPI1008774A2 (pt) espiroamida substituída
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
BRPI1005525A2 (pt) compostos de azaazuleno
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
BR112012003868A2 (pt) Compostos orgânicos
DE112009005323A5 (de) Hebelarmprüfmaschine
UY33156A (es) Nuevos compuestos tienopirrol
DE112010004249A5 (de) Spindelaktor
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BRPI1008070A2 (pt) tricianoboratos
BR112012004964A2 (pt) girocóptero
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti
BR112012009784A2 (pt) composto benzazepínico
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas